Industry news round-up: updates from August 2023
Discover what’s been happening this month in our regular monthly column, where we summarize a selection of key industry developments that took place in August 2023.
From industry
Peterson Health Technology Institute launched for real-world evaluation of digital health technologies
New Peterson Health Technology Institute will independently analyze real-world clinical benefits and economic impact of healthcare innovations.
xCures announces partnership with Aetion to support real-world evidence research collaboration with FDA
xCures partners with Aetion to provide robust, regulatory-grade real-world data (RWD) to progress their collaboration with the US Food and Drug Administration (FDA) Oncology Center of Excellence.
US government and patient groups fight back at lawsuits aimed at blocking drug price negotiation provisions of the Inflation Reduction Act
Department of Health and Human Services files motion in US court to dismiss one of the six lawsuits challenging the Inflation Reduction Act (IRA) with support announced by a coalition of patient and consumer groups.
Catch up on our coverage of the Inflation Reduction Act in our dedicated Spotlight.
CADTH invites industry representatives for new industry task force on real-world data for post-market drug evaluations
CADTH announces it is establishing a new industry task force to advance use of real-world data for post-market drug evaluations and issues public call inviting industry representatives to participate.
Target RWE launches new analytical solutions to advance real-world evidence generation
New solutions by Target RWE, Syndicated Science™ Insights, offer users access to robust analytics of large claims databases and are designed to address research hypotheses regardless of the data source.
PicnicHealth moves into oncology real-world data with AstraZeneca breast cancer partnership
PicnicHealth branches into oncology-focused real-world data in announcing a multi-year strategic partnership with AstraZeneca to accelerate early breast cancer evidence development and research.
CMS unveils first 10 drugs subject to price negotiations under the Inflation Reduction Act
Top-selling drugs by Bristol Myers Squibb, AstraZeneca and Novo Nordisk amongst those selected for the first cycle of price negotiations under the Inflation Reduction Act (IRA).
IQ RWD working group provides industry perspective on clinical pharmacology applications of RWD and RWE in drug development
The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) real-world data (RWD) working group has published a White Paper, providing industry perspectives on clinical pharmacology applications of RWD and real-world evidence (RWE) in drug development and approval.
